Lead Product(s) : Ipatasertib,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care plus placebo met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients wi...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2020
Lead Product(s) : Ipatasertib,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable